IGXT (Mcap $31 M) Submits new NDA in March + 3x NDA/ANDA filings in 1H 2013 + Profitable in 2013
This is a real once in a lifetime opportunity ..GLTA
Intelgenx launched their first drug Forfivo in October this will push this unknown Gem into Profitability by in 2013 because of its very low burn-rate of just $1.2 Mil a year !
IGXT Submits next NDA to the FDA for an Anti-Migraine Versafilm last Week and another 3x More NDA/ANDA filings expected in 1H 2013 includes a potency drug which is better than Viagra . This Goldmine has 9x Drugs in their Mega Pipeline which will be all on the Market within next 2-3 years .
IGXT has NO DEBT and current Market cap of just $31 M is really a BIG BIG BARGAIN .
My Target is $8-12 within 2 Years .GLTA
Market Cap : $31 M
Cash: $3.5 M
Burn-Rate : $1.2 M a year
Price : $0.63
Shares Out : 50 M ( 27 M shares are held by Insiders & Institutions)
"We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx.
March 27, 2013 IntelGenx Corp. a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.